HEALTH

Roche launches pilot program to help diabetes patients with co-pay savings

BY Michael Johnsen

INDIANAPOLIS Roche on Friday announced the launch of its new eVoucherRx pilot program in California, a program designed to make it easier for patients with diabetes to receive their co-pay savings on Accu-Chek test strips.

The program, active now at participating pharmacies, ensures patients with diabetes that their co-pay for Accu-Chek test strips will not exceed $25. The program provides a discount of up to $40 per month, potentially lowering a patient’s cost of blood glucose monitoring supplies by up to $480 per year.

“Lowering the patient’s financial responsibility for diabetes therapy positively influences adherence and persistency in the self-management of their disease, especially during these challenging economic times,” stated Dan Kane, Roche VP marketing. “eVoucherRx also helps prescribing physicians know that more of their patients will be able to afford their diabetes supplies.”

eVoucherRx is a program that works in real time at the point of dispensing, which means patients do not need to do anything  other than go to a participating pharmacy. To find a list of participating pharmacies, patients are encouraged to go online and visit www.accu-chek.com/evoucher.

The eVoucherRx program is administered by RelayHealth for patients with commercial third-party health insurance. The program is not open to patients age 65 or older, cash-paying customers, patients on Medicare, Medicaid or those subsidized by other government-funded plans.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Bionorica announces Wolf Aulenbacher as president

BY Michael Johnsen

SAN CLEMENTE, Calif. Bionorica earlier this month named Wolf Aulenbacher to the position of president.

Aulenbacher succeeds Scott Bukow, who has resigned to pursue other opportunities, the company stated. “[Bukow] is to be commended for his contributions in helping achieve significant retail distribution in the U.S.,” the company stated. “He remains committed to assisting with any questions or issues that may arise during this transitionary period.”

Aulenbacher is an experienced sales and marketing executive in the U.S. phyto-pharmaceutical and dietary supplement arenas since 1984 and has been a consultant to Bionorica since 2004.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Biocodex appoints new VP, managing director

BY Michael Johnsen

SAN BRUNO, Calif. Biocodex, manufacturer of Florastor and Florastor Kids probiotic supplements, on Thursday announced the appointment of Marc Rohman as VP and managing director of Biocodex, Inc., the French company’s U.S. subsidiary.

According to Nicolas Coudurier, international director of Biocodex, the U.S. market is a key priority for the company for its planned strategic expansion in the pharmaceutical arena.

“Florastor has been a tremendous success worldwide, and we feel there is great potential for the U.S. to be one of our largest footprints for this and other brands,” Coudurier said. “We’re thrilled to have someone with [Rohman’s] vast pharma expertise, not only on the marketing side, but also on the medical affairs side, to lead our foray into new U.S. product offerings.”

Prior to joining Biocodex, Rohman was part of the senior management team at FlowMedica where he was responsible for directing the company’s collaboration efforts for targeted renal therapy. While at FlowMedica, he also directed the collaborative pharma and other general business development efforts, as well as lead marketing, market development and general promotion of the company.

“Maximizing the potential of the Florastor brand is going to be a key priority for me, but at the same time, I will also be focusing on strategic alliances to build the company’s U.S. portfolio,” Rohman said. “Within the next five years or so, I’d like to see the U.S. arm of Biocodex bring at least two or more products to market.”

In addition to his work at FlowMedica, Rohman also worked for leading biotech and pharmaceutical companies, such as Scios, which was acquired by Johnson & Johnson in 2003, Mallinckrodt (now Tyco Healthcare), Boehringer Mannheim, Knoll Pharmaceuticals and Marion Labs.

Rohman holds a Bachelor of Arts degree in advertising from Michigan State University.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?